Rapamycin Treatment for ALS

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

December 15, 2020

Study Completion Date

February 15, 2022

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Rapamycin

tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage

DRUG

Placebo Oral Tablet

tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage

Trial Locations (7)

41126

Centro Sla, Ospedale Civile S. Agostino Estense, A.O.U. Modena, Modena

Unknown

Centro Sla, Irccs A.O.U. S.Martino Ist, Genova, Genova

Centro Clinico Nemo, Fondazione Serena Onlus, Milano, Milan

Centro Sla, Irccs Istituto Carlo Besta, Milano, Milan

Centro Sla, A.O.U. Maggiore Della Carita', Novara, Novara

Centro Sla, Universita' Di Padova, Padua

Centro Sla, Universita' Di Torino, Torino

All Listed Sponsors
collaborator

University of Modena and Reggio Emilia

OTHER

collaborator

Azienda Ospedaliero Universitaria Maggiore della Carita

OTHER

collaborator

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

OTHER

collaborator

University of Turin, Italy

OTHER

collaborator

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

OTHER

collaborator

Azienda Ospedaliera Niguarda Cà Granda

OTHER

collaborator

Fondazione Salvatore Maugeri

OTHER

collaborator

University of Padova

OTHER

lead

Azienda Ospedaliero-Universitaria di Modena

OTHER

NCT03359538 - Rapamycin Treatment for ALS | Biotech Hunter | Biotech Hunter